-
Pipeline
Inflammatory
-
Field
-
Program
-
Indications
-
PCC
-
IND
-
Phase I
-
Phase II
-
Phase III
-
NDA
-
info
Inflammatory
-
MY008
PNH, C5-naïve
-
MY008
PNH, C5-inadequate
-
MY004
RA (China)
-
MY004
RA (United States)
-
MY004
AD/CSU
-
MY009
UC
-
QR059
PNH (Mono)
-
QR059
PNH (Combo)
Inflammatory
Program:MY008
Indications:PNH, C5-naïve
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Inflammatory
Program:MY008
Indications:PNH, C5-inadequate
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Inflammatory
Program:MY004
Indications:RA (China)
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Inflammatory
Program:MY004
Indications:RA (United States)
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Inflammatory
Program:MY004
Indications:AD/CSU
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Inflammatory
Program:MY009
Indications:UC
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Inflammatory
Program:QR059
Indications:PNH (Mono)
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Inflammatory
Program:QR059
Indications:PNH (Combo)
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Cardiorenal
-
Field
-
Program
-
Indications
-
PCC
-
IND
-
Phase I
-
Phase II
-
Phase III
-
NDA
-
info
Cardiorenal
-
MY008
IgAN
-
QR12000
Moderate-to-Severe Primary Hypertension
-
MY004
IgAN
Cardiorenal
Program:MY008
Indications:IgAN
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Cardiorenal
Program:QR12000
Indications:Moderate-to-Severe Primary Hypertension
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Cardiorenal
Program:MY004
Indications:IgAN
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Pulmonology
-
Field
-
Program
-
Indications
-
PCC
-
IND
-
Phase I
-
Phase II
-
Phase III
-
NDA
-
info
Pulmonology
-
QR052
Cough (China)
-
QR052
Cough (United States)
-
QR056251
IPF
-
QR055
IPF
Pulmonology
Program:QR052
Indications:Cough (China)
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Pulmonology
Program:QR052
Indications:Cough (United States)
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Pulmonology
Program:QR056251
Indications:IPF
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Pulmonology
Program:QR055
Indications:IPF
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ
Ophthalmology
-
Field
-
Program
-
Indications
-
PCC
-
IND
-
Phase I
-
Phase II
-
Phase III
-
NDA
-
info
Ophthalmology
-
MY155
AMD
Ophthalmology
Program:MY155
Indications:AMD
PCC
IND-Enabling
IND
Clinical Phase I
Clinical Phase Ⅱ
Clinical Phase Ⅲ